Hiroko Kimura

Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.

KBI Biopharma, Inc. provides drug development and contract manufacturing services. It helps client partners accelerate and optimize drug development and manufacturing programs by offering an extensive suite of expert development and manufacturing services. The firm offers services to global pharmaceutical and biotechnology companies, and academic and non-profit organizations. The company was founded in 1996 and is headquartered in Durham, NC.

HuBit Genomix KK is a Japanese pharmaceutical development company that conducts clinical trials and research on pharmaceuticals to develop diagnostic drugs. The company is based in Tokyo, Japan. The company analyzes and utilize valuable information to create "diagnosis methods" and "pharmaceuticals" that satisfy medical amenities. HuBit Genomix KK was acquired by Celera Group on March 20, 2001.

Schroder Investment Management (Japan) Ltd. (SIM-JP) is the investment management subsidiary of Schroder International Finance BV, ultimately owned by Schroders plc (LON: SDR, ADR: SHNWY) in Great Britain. Founded in 1985, the firm is headquartered in Tokyo and provides asset management services to private individuals and institutions. SIM-JP also manages a range of investment products and distributes products managed within the parent group. The firm is a responsible investor and signatory to the UN Principles for Responsible Investment (UN PRI).

The Children's Mercy Hospital provides pediatric health care services. It offers abdominal pain program, adolescent medicine, anesthesiology, bioethics, bone marrow transplantation, burn and trauma care, cardiology, child abuse and neglect, cleft palate and craniofacial, dentistry, dermatology, down syndrome clinic, eating disorders center, endocrinology and diabetes, epilepsy center, fetal health center, gastroenterology, genetics, gynecology, hand clinic and surgery, hematology, heart center, imaging, kidney and liver transplant, medical imaging, neonatology, neurology, nutrition services, ophthalmology, pain management, pathology and laboratory medicine, pharmacology, radiology, respiratory care, sexual differentiation treatment, sleep disorders program, surgery, telemedicine, urgent care, urologic surgery, and weight management services. The company was founded in June 1897 and is headquartered in Kansas City, MO.

Part of Bayer AG, Monsanto Japan Ltd. is a Japanese company that manufactures a wide range of genetically altered seeds, fertilizers, and agrochemicals. The company is based in Tokyo, Japan.

Astellas Venture Management LLC (Astellas Venture Management) is a venture capital subsidiary of Astellas Pharma Inc founded in 2000. The firm is headquartered in San Francisco, California.

Anaeropharma Science, Inc. operates as a holding company that engages in the research and development of therapeutics to target hypoxic environment in solid cancers. It develops bifidobacterium technologies to create anti-cancer drugs. The firm's bifidobacterium therapeutics accumulates to the solid tumor when intravenously injected. The company was founded by Minoru Fujimori and Shunichiro Taniguchi on August 9, 2004 and is headquartered in Tokyo, Japan.

Life Science Management, Inc. provides consulting services for businesses in the life science and healthcare industries. The Japanese company's focus is on helping these businesses to succeed and grow.

The Innovation Network Corporation of Japan (INCJ), a unique public-private partnership aimed at promoting innovation and enhancing the value of businesses in Japan, was launched in July 2009. Leveraging the rich history of Japanese technological prowess, the INCJ aims to provide financial, technological and management support in order to promote the creation of next-generation businesses through 'open innovation,' or the flow of technology and expertise beyond the boundaries of existing organizational structures. The INCJ will draw on funding as well as management and technological expertise from the public and private sectors. The INCJ is actively reviewing various investment opportunities in areas of environment and energy, electronics and IT, bio-tech, and infrastructure such as water supply, railway service, and nuclear power supply. Each investment will be thoroughly vetted to ensure it meets the exacting standards of the INCJ's Innovation Network Committee, which will make the final investment decisions. The INCJ is capitalized at 92 billion yen, with the Japanese government injecting 82 billion yen and 19 private corporations (refer to details in Appendix below) providing a further 10 billion yen. The government will also provide guarantees up to a total of 800 billion yen for INCJ investments, giving it an investment capability of approximately 900 billion yen (US$10 billion). The INCJ will be established for a period of 15 years.

Japan Medical Information Research Institute, Inc. engages in the collection, analysis, marketing, and consulting of medical information. The company was founded on July 14, 2005 and is headquartered in Tokyo, Japan.

NapaJen Pharma, Inc. develops drug delivery technology solutions through cellular transport pathways. Its products include lead platform and drug delivery. The firm specializes in the development of novel drug delivery systems by utilizing natural transport pathways whose cells are used to move molecular cargo into themselves and across internal compartments. The company was founded by Dr. Kazuo Sakurai and Hironori Ando in December 2004 and is headquartered in Burlingame, CA.

Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa.

PRISM Pharma Co., Ltd. operates as a pharmaceutical company that focuses on discovery and development of small molecules to modulate protein-protein interactions. It utilizes protein secondary structure mimetic library, which modulates intracellular protein and protein interactions. The firm develops an anti-cancer drug CP/Catenin inhibitor PRI-724 that acts on both cancer cells and cancer stem cells that can switch from proliferation to differentiation. The company was founded by Hiroyuki Kouji on November 2, 2006 and is headquartered in Fujisawa, Japan.

Megakaryon Corp. operates as an pluripotent stem cells research laboratory. It produce platelets and red blood cells from iPS cell lines, and to develop blood products that do not depend on blood donations. The firm specializes in development of technologies to produce and store induced pluripotent stem cell derived human T cells. Megakaryon was founded by Genjiro Miwa on September 9, 2011 and is headquartered in Kyoto, Japan.

Quantum Biosystems, Inc. is a holding company that develops single-molecule DNA sequencers. It develops and commercializes sequencers based on quantum mechanics. The company was founded by Toshihiko Honkura and Masateru Taniguchi on January 7, 2013 and is headquartered in Osaka, Japan.

Atonarp, Inc. provides chemical analysis solutions and systems. The firm develops the Smart Spectrometer technology that focus on industrial gas process analytics applications in the energy, pharmaceutical, petrochemical and semiconductor industries. The company was founded by Tomoyoshi Sato and Prakash S. Murthy in November 2009 and is headquartered in Minato-Ku, Japan.

AccuRna, Inc. researches and develops nucleic acid-based drugs using drug delivery system technologies. The company was founded on December 18, 2015 and is headquartered in Tokyo, Japan.

Axial Therapeutics, Inc. provides biopharmaceuticals. It is harnessing the link between the human get microbiome and the central nervous system to develop a new class of biotherapeutics to improve the quality of life for people with neurological diseases and disorders. The company was founded by Sarkis Mazmanian and David H. Donabedian and is headquartered in Boston, MA.

UTokyo Innovation Platform Co.,Ltd. (UTokyo IPC) is a Venture Capital firm, a subsidiary of University of Tokyo founded in 2016. UTokyo Innovation Platform Co.,Ltd. is headquartered in Tokyo.

HanaVax, Inc. develops nasal vaccine against infectious diseases. It develops pneumococcal nasal vaccine to prevent pneumonia, sepsis and otitis media. The company was founded by Hosei Ou on December 27, 2017 and is headquartered in Tokyo, Japan.

SCOHIA PHARMA, Inc. is a drug discovery venture that focuses on lifestyle-related diseases. The company is based in Fujisawa, Japan. The Japanese company has a strong development pipeline and an experienced R & D team that specializes in drug discovery, including compound creation, drug efficacy evaluation, and clinical development. The CEO of the company is Masanori Watanabe.

NeoPhore Ltd. engages in discovery and development of small molecules inhibitors to treat cancer. The company is headquartered in Kings Cross, London, the United Kingdom.

Braizon Therapeutics, Inc. is a Japanese company that engages in researching and developing drugs. The company was founded in 2015 by Mariko Tosu. The CEO is Bunichi Wanibuchi.

Modulus Discovery, Inc. preclinical stage drug Discovery Company. It is focused on rapid design and generation of small molecule clinical candidates for disease targets through the use of its cutting-edge computational drug discovery expertise and unique biology insights. The company was founded by Shun Roy Kimura And Kazuki Ohno and is headquartered in Minato-ku, Japan.

PuREC KK is a company based in Japan that aims to revolutionize the future of regenerative medicine by developing a high-purity mesenchymal stem cell culture technology called REC (Rapidly Expanding Cell). REC has approximately 1000 times more pharmacological efficacy in terms of proliferation and differentiation compared to normal mesenchymal stem cells, making it effective in treating a wide range of diseases. The Japanese company was founded in 2016 by Shotai Kobayashi.

Metagen Therapeutics, Inc. is a company based in Tsuruoka, Japan. The Japanese company was founded in 2020 by Taku Nakahara, Takuji Yamada, Shinji Fukuda, and Dai Ishikawa. Taku Nakahara has been the CEO since 2020.

UE Resorts International, Inc. is a holding company, which engages in the development, owning, and operation of Okada Manila, a casino resort. It is also involved in acquiring and managing inns, apartments, private clubs, pension houses, convention halls, lodging houses, restaurants, cocktail bars, and gaming and entertainment businesses. The company was founded on March 10, 2021 and is headquartered in Parañaque, Philippines.

FALCON Research & Consulting Ltd. provides financial consultation, market analytics, and surveying services.